---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-015003"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:22:34.504364+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PMGC subsidiary NorthStrive signs exclusive license for EL-22/EL-32 in animal health

## Summary
- Definitive license with Modulant Biosciences for myostatin-engineered probiotic EL-22 and EL-32.
- Modulant gets exclusive, royalty-bearing, sublicensable license for non-human animal health worldwide except Korea.
- Modulant pays value (undisclosed) and handles development, manufacturing, regulatory, commercialization.
- License excludes human pharmaceutical applications; shared ownership of improvements.
- Follows binding term sheet from May 2025; no assurance of commercial success.

## SEC filing metadata
- accession: 0001213900-26-015003
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390026015003/0001213900-26-015003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390026015003/ea0276475-8k_pmgc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-015003
- JSON: https://secwatch.observer/filing/0001213900-26-015003.json
- Plain text: https://secwatch.observer/filing/0001213900-26-015003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.